Start Date
August 31, 2015
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
Cobimetinib
A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
Vemurafenib
A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Collaborators (1)
Genentech, Inc.
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER